Floatz logo

Recombinant Fowlpox-Gm-Csf

Gallbladder Adenocarcinoma

National Cancer Institute (NCI)vaccinePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Gallbladder Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Irinotecan
Georgetown University
Phase 3BB
Atezolizumab
Georgetown University
Phase 3B
Bortezomib
National Cancer Institute (NCI)
Phase 2CCC
Selumetinib
National Cancer Institute (NCI)
Phase 2CCC
mk-2206
National Cancer Institute (NCI)
Phase 2CCC

View all 14 →

Same molecule, other indications

Recombinant Fowlpox-Gm-Csf is also rated in:

prostate neoplasmDormant
CCC
Indicative · Phase 1/2
55 / 100
View asset →
salivary gland cancerDormant
CC
Indicative · Phase 1
47 / 100
View asset →
pancreatic adenocarcinomaDormant
CC
Indicative · Phase 1
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →